Algernon Pharmaceuticals finding new uses for safe, older drugs
Algernon Pharmaceuticals Inc (OTCMKTS:BTHCF) CEO Christoper Moreau sat down with Proactive’s Steve Darling at the 12th annual LD Micro Conference in Bel Air, California. The Vancouver, British Columbia-based clinical stage pharmaceutical development company is advancing its lead compounds for non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease and idiopathic pulmonary fibrosis. …
Repurposed Anti-fibrotic Medication, NP-120, Set for Phase 2 Testing for IPF
by Joana Carvalho on August 2nd, 2019 Algernon, a pharmaceutical company focused on repurposing generic medications that are not available in the U.S. or EU, is investigating if NP-120 might treat IPF due to its potent anti-fibrotic properties. Of note, drug repurposing refers to the process of testing a medication with established safety in conditions other than those for which it was originally intended. NP-120 belongs to a class of drugs known as N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonists. Algernon is currently investigating how its mechanism of action may benefit people with IPF. The company recently announced preclinical study results …
Vancouver company repurposes Soviet Union doping drug to cure kidney disease
by Kate Wilson on August 1st, 2019 Today, Algernon announced that Bemethyl (NP-135) and Bromantane (NP-160)—both drugs developed by the Soviet Union to boost the performance of its military and Olympic athletes—are effective for treating chronic kidney disease (CKD), and non-alcoholic steatohepatitis (NASH): inflammation caused by a buildup of fat in the liver. The company confirmed in multiple animal studies that the two substances were able to reduce fibrosis—a kind of scarring caused by a buildup of connective tissue—at highly statistically significant rates. A press release suggests that the drugs outperformed known anti-fibrotic agents named Telmisartan and Cenicriviroc. “We are …
WATCH: Algernon Pharmaceuticals – Investor Hub
Recently, Algernon CEO Christopher J. Moreau and CSO Dr. Mark Williams were asked to talk about the company’s technology and value proposition. …
Taking Unparalleled Results to Treat the Next Epidemic
Since donning its new corporate identity earlier this year, Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) has been busy advancing its research and its business. Much like the classic novel the clinical stage Company derived its name from, which built its theme around change, Algernon is shifting to become a phase II clinical trial Company. Having changed its name to Algernon in February 2019, the corporate shift was intended to align its operation with its main strategy to be a global leader in the treatment of liver disease, non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). NASH is a common liver …
About Us
